These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26881937)

  • 1. Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells.
    Lin X; Liao Y; Chen X; Long D; Yu T; Shen F
    Cancer Biother Radiopharm; 2016 Mar; 31(2):37-43. PubMed ID: 26881937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro.
    Chen X; Liao Y; Long D; Yu T; Shen F; Lin X
    Int J Mol Med; 2017 Jul; 40(1):235-242. PubMed ID: 28534969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.
    Lin X; Liao Y; Xie J; Liu S; Su L; Zou H
    Cancer Biother Radiopharm; 2014 Nov; 29(9):376-86. PubMed ID: 25379611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinblastine differs from Taxol as it inhibits the malignant phenotypes of NSCLC cells by increasing the phosphorylation of Op18/stathmin.
    Shen F; Long D; Yu T; Chen X; Liao Y; Wu Y; Lin X
    Oncol Rep; 2017 Apr; 37(4):2481-2489. PubMed ID: 28259950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice.
    Lin X; Yu T; Zhang L; Chen S; Chen X; Liao Y; Long D; Shen F
    Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):611-620. PubMed ID: 27289016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction of exogenous wild‑type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor‑κB in non‑small cell lung cancer NCI‑H1299 cells.
    Chen S; Zhao Y; Shen F; Long D; Yu T; Lin X
    Oncol Rep; 2019 Mar; 41(3):2051-2059. PubMed ID: 30628717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNAi targeting STMN alleviates the resistance to taxol and collectively contributes to down regulate the malignancy of NSCLC cells in vitro and in vivo.
    Long D; Yu T; Chen X; Liao Y; Lin X
    Cell Biol Toxicol; 2018 Feb; 34(1):7-21. PubMed ID: 28589243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro neutralization of autocrine IL‑10 affects Op18/stathmin signaling in non‑small cell lung cancer cells.
    Zhao Y; Chen S; Shen F; Long D; Yu T; Wu M; Lin X
    Oncol Rep; 2019 Jan; 41(1):501-511. PubMed ID: 30320402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.
    Han ZX; Wang HM; Jiang G; Du XP; Gao XY; Pei DS
    Cancer Biother Radiopharm; 2013 Jun; 28(5):398-405. PubMed ID: 23496232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of RhoGDIα induces apoptosis and increases lung cancer cell chemosensitivity to paclitaxel.
    Rong F; Li W; Chen K; Li DM; Duan WM; Feng YZ; Li F; Zhou XW; Fan SJ; Liu Y; Tao M
    Neoplasma; 2012; 59(5):541-50. PubMed ID: 22668020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus-encoded LMP1 triggers regulation of the ERK-mediated Op18/stathmin signaling pathway in association with cell cycle.
    Lin X; Tang M; Tao Y; Li L; Liu S; Guo L; Li Z; Ma X; Xu J; Cao Y
    Cancer Sci; 2012 Jun; 103(6):993-9. PubMed ID: 22417000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells.
    Suyama H; Igishi T; Sano H; Matsumoto S; Shigeoka Y; Nakanishi H; Endo M; Burioka N; Hitsuda Y; Shimizu E
    Int J Oncol; 2004 Jun; 24(6):1499-504. PubMed ID: 15138593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
    Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
    Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin.
    Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F
    Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells.
    Nishio K; Nakamura T; Koh Y; Kanzawa F; Tamura T; Saijo N
    Cancer; 2001 Apr; 91(8):1494-9. PubMed ID: 11301397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Op18/stathmin as a potential target of ASK1-p38 MAP kinase cascade.
    Mizumura K; Takeda K; Hashimoto S; Horie T; Ichijo H
    J Cell Physiol; 2006 Feb; 206(2):363-70. PubMed ID: 16110469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.
    Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z
    Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
    Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
    PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.